Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DFC0V4
|
|||
| Drug Name |
CB-5339
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [1] | ||
| Company |
Cleave Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Valosin-containing protein p97 (VCP) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| Legionellosis | ||||
| Reactome | Hedgehog ligand biogenesis | |||
| Hh mutants that don't undergo autocatalytic processing are degraded by ERAD | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04402541) Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Cleave Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.